The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab.

Sanjeev Deva; Michael Millward; Michael Friedlander; Hui K. Gan; Lisa G. Hovarth; Jong-Seok Lee; Andrew Hill; Shahneen Sandhu; Liang Liang; Jingwen Shi; Yun Zhang; Yang Shi; Xiaopeng Ma; Xikun Wu; Zhirong Shen; Jayesh Desai

doi:10.1158/1538-7445.AM2022-LB511

The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab.

Sanjeev Deva, Michael Millward, Michael Friedlander, Hui K. Gan, Lisa G. Hovarth, Jong-Seok Lee, Andrew Hill, Shahneen Sandhu, Liang Liang, Jingwen Shi, Yun Zhang, Yang Shi, Xiaopeng Ma, Xikun Wu, Zhirong Shen, Jayesh Desai

Internal Medicine

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Article number	LB511
Number of pages	2
Journal	Cancer Research
Volume	82
Issue number	12
DOIs	https://doi.org/10.1158/1538-7445.AM2022-LB511
Publication status	Published - 15 Jun 2022
Event	113th Annual Meeting of the American-Association-for-Cancer-Research - New Orleans, United States Duration: 8 Apr 2022 → 13 Apr 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1158/1538-7445.AM2022-LB511Licence: Unspecified

Cite this

Deva, S., Millward, M., Friedlander, M., Gan, H. K., Hovarth, L. G., Lee, J.-S., Hill, A., Sandhu, S., Liang, L., Shi, J., Zhang, Y., Shi, Y., Ma, X., Wu, X., Shen, Z., & Desai, J. (2022). The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab. Cancer Research, 82(12), Article LB511. https://doi.org/10.1158/1538-7445.AM2022-LB511

@article{9bef03666cd64f9f869c76c08b12292e,

title = "The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab.",

author = "Sanjeev Deva and Michael Millward and Michael Friedlander and Gan, {Hui K.} and Hovarth, {Lisa G.} and Jong-Seok Lee and Andrew Hill and Shahneen Sandhu and Liang Liang and Jingwen Shi and Yun Zhang and Yang Shi and Xiaopeng Ma and Xikun Wu and Zhirong Shen and Jayesh Desai",

year = "2022",

month = jun,

day = "15",

doi = "10.1158/1538-7445.AM2022-LB511",

language = "English",

volume = "82",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research (AACR)",

number = "12",

note = "113th Annual Meeting of the American-Association-for-Cancer-Research , AACR ; Conference date: 08-04-2022 Through 13-04-2022",

}

Deva, S, Millward, M, Friedlander, M, Gan, HK, Hovarth, LG, Lee, J-S, Hill, A, Sandhu, S, Liang, L, Shi, J, Zhang, Y, Shi, Y, Ma, X, Wu, X, Shen, Z & Desai, J 2022, 'The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab.', Cancer Research, vol. 82, no. 12, LB511. https://doi.org/10.1158/1538-7445.AM2022-LB511

TY - JOUR

T1 - The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab.

AU - Deva, Sanjeev

AU - Millward, Michael

AU - Friedlander, Michael

AU - Gan, Hui K.

AU - Hovarth, Lisa G.

AU - Lee, Jong-Seok

AU - Hill, Andrew

AU - Sandhu, Shahneen

AU - Liang, Liang

AU - Shi, Jingwen

AU - Zhang, Yun

AU - Shi, Yang

AU - Ma, Xiaopeng

AU - Wu, Xikun

AU - Shen, Zhirong

AU - Desai, Jayesh

PY - 2022/6/15

Y1 - 2022/6/15

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000892509500011?SID=EUW1ED0F8DJeyy75FF4UMJDlSowp0

U2 - 10.1158/1538-7445.AM2022-LB511

DO - 10.1158/1538-7445.AM2022-LB511

M3 - Abstract/Meeting Abstract

SN - 0008-5472

VL - 82

JO - Cancer Research

JF - Cancer Research

IS - 12

M1 - LB511

T2 - 113th Annual Meeting of the American-Association-for-Cancer-Research

Y2 - 8 April 2022 through 13 April 2022

ER -

The combination of hyper-amplification and tumor mutational burden as a pan-cancer biomarker in patients treated with tislelizumab.

UN SDGs

Access to Document

Other files and links

Cite this